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Abstract
Background: More people than ever before are currently living with a diagnosis of cancer and the number of
people concerned is likely to continue to rise. Cancer survivors are at risk of developing a second primary cancer
(SPC). This study aims to investigate the risk of SPC in Switzerland.
Methods: The study cohort included all patients with a first primary cancer recorded in 9 Swiss population-based
cancer registries 1981–2009 who had a minimum survival of 6 months, and a potential follow-up until the end of
2014. We calculated standardized incidence ratios (SIR) to estimate relative risks (RR) of SPC in cancer survivors
compared with the cancer risk of the general population. SIR were stratified by type of first cancer, sex, age and
period of first diagnosis, survival period and site of SPC.
Results: A total of 33,793 SPC were observed in 310,113 cancer patients. Both male (SIR 1.18, 95%CI 1.16–1.19) and
female (SIR 1.20, 95%CI 1.18–1.22) cancer survivors had an elevated risk of developing a SPC. Risk estimates varied
substantially according to type of first cancer and were highest in patients initially diagnosed with cancer of the
oral cavity and pharynx, Hodgkin lymphoma, laryngeal, oesophageal, or lung cancer. Age-stratified analyses revealed
a tendency towards higher RR in patients first diagnosed at younger ages. Stratified by survival period, risk
estimates showed a rising trend with increasing time from the initial diagnosis. We observed strong associations
between particular types of first and SPC, i.e. cancer types sharing common risk factors such as smoking or alcohol
consumption (e.g. repeated cancer of the oral cavity and pharynx (SIRmales 20.12, 95%CI 17.91–22.33; SIRfemales 37.87,
95%CI 30.27–45.48).
Conclusion: Swiss cancer survivors have an increased risk of developing a SPC compared to the general
population, particularly patients first diagnosed before age 50 and those surviving more than 10 years. Cancer
patients should remain under continued surveillance not only for recurrent cancers but also for new cancers. Some
first and SPCs share lifestyle associated risk factors making it important to promote healthier lifestyles in both the
general population and cancer survivors.
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Background
More people than ever before are currently living with a
diagnosis of cancer and the number of people concerned
is likely to continue to rise [1–3]. In the US, for example,
3.6 million cancer survivors were alive in 1975. As of Janu-
ary 2019, the number rose to 16.9 million and that num-
ber is expected to increase to 26.1 million by 2040 [4].
Apart from total population growth [5], this trend results
from an increase in life expectancy [6], population ageing
[5], and continuing improvements in survival linked to
better cancer detection and improvement of treatments
[7, 8]. A consequence of surviving cancer is the risk of be-
ing diagnosed with a second primary cancer (SPC). Cancer
survivors might be especially prone to develop a new pri-
mary cancer due to various reasons including common
etiologic risk factors (i.e. environmental exposures, genet-
ics, lifestyle choices) and late effects of cancer treatment
[9]. SPC is not only a particularly difficult event for pa-
tients but could be also an important prognostic factor
among cancer survivors [10].
Several studies outside of Switzerland reported that
cancer survivors have an increased risk for being diag-
nosed with a new primary cancer compared to the gen-
eral population [11–17]. However, risk estimates vary
strongly by country/region and time period investigated.
An older study from Denmark [18], for example, ob-
served a slightly elevated risk of SPC exclusively for
those surviving 30 year or more after first diagnosis
whereas a recent French study found similar and sub-
stantially elevated risks across survival periods [13].
Apparent discrepancies in risk estimates might be
partly explained by methodological differences between
studies (e.g. definition of metachronous primary cancers,
length of follow-up) and/or problems within studies (e.g.
incomplete case ascertainment). However, due to poten-
tial or known differences between countries and regions
(e.g. environmental exposure, standard treatment regi-
mens) and their populations (e.g. risk behaviour, genetic
susceptibility), SPC need individual investigations by
country or region of interest. The only systematic inves-
tigation of risks of SPC in Switzerland dates back to
1993 using data from a single canton cancer registry
[19]. A more recent publication covering less than 15%
of the Swiss population presented frequencies of first
and SPC but no risk estimates of SPC [14]. Therefore,
this study aims to investigate the risk of SPC in
Switzerland including data of all cantonal cancer regis-
tries eligible for this study.
Methods
Data on cancer diagnoses and vital status information
were obtained from Swiss cantonal cancer registries with
at least 15 years of consecutive incidence data between
1981 and 2014 (Basel-Stadt/Basel-Landschaft (BS/BL)
(1981–2011), Geneva (1981–2014), Grison (1989–2014),
Glarus (1992–2014), Neuchâtel (1981–2014), St. Gallen-
Appenzell (1981–2014), Ticino (1996–2014), Valais
(1989–2014), Vaud (1981–2014) and Zurich (1981–
2014)). The national population coverage for this study
by calendar year varied from 47.3 to 58.1%. Complete-
ness of case ascertainment in Switzerland is overall high
across cancer registries [20]. The proportion of death
certificate only cases (DCO) and microscopically verified
cases for the registries under study was overall 1.3 and
88.6%, respectively. Nevertheless, in some cancer regis-
tries, a systematic and complete linkage of incidence
cases against mortality data was not carried out for all
calendar years [21]. After exclusion of the affected inci-
dence data, the overall proportion of DCO slightly in-
creased to 1.6%.
A SPC was defined as first subsequent primary cancer
occurring at least 6 months after the first cancer [22].
We identified primary cancers based on the rules de-
fined by the International Association of Cancer Regis-
tries (IACR), International Association for Research on
Cancer (IARC) and the European Network of Cancer
Registries (ENCR) [23].
Vital status information was collected by active (verifica-
tion of vital status with the cantonal and/or community
inhabitant control offices) and passive follow-up (match-
ing registered cancer cases with mortality data of the
Federal Statistical Office). Due to the lack of a unique
patient identifier in the federal mortality data, passive link-
age was done using probabilistic matching algorithms.
Proportion of cases with incomplete follow-up (i.e. last
sign of life before 31st December 2014. (BS/BL: 2011) with
no SPC) was 15.7% and ranged by registry from 0 to
24.1%. The variation in follow-up completeness is due to
several causes such as the proportion of migrant popula-
tion, and cantonal organization of cancer registration with
different financial resources and legal frameworks. In
some cantons, for example, individual inquiry letters have
to be sent to inhabitant control offices whereas in other
cantons electronic and automatized solutions are well
established [24].
Incomplete vital status information artificially de-
creases follow-up times among patients without SPC
leading to an overestimation of SPC risks [25]. We
addressed incompleteness of vital status follow-up
using multiple imputation methods. We created 25
complete datasets. For each dataset, the analyses were
performed separately and merged afterwards using
Rubin’s Rules [26]. Incomplete follow-up times were
imputed by sex and cancer type using left censored
regressions with time period between diagnosis and
last follow-up as lower limit. The imputation models
included the following predictors: both age at time of
diagnosis and incidence period as linear and quadratic
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term, and language region of residence (French-Ital-
ian, German) as categorical variable. Based on im-
puted follow-up times, corresponding follow-up dates
were calculated censoring at 31st of December 2014
(BS/BL: 31st of December 2011). Language region of
residence was added to the models due to known re-
gional differences in lifestyle-associated risk factors
(i.e. alcohol and tobacco consumption [27]), screening
behaviour [28, 29] and treatment regimens [30].
The final study cohort included all patients first diag-
nosed with an invasive cancer (excluding non-melanoma
skin cancer) between 1981 and 2009 (BS/BL: 2006)
allowing for a minimum of 5 years after first diagnosis
to determine the presence of a SPC. Patients with syn-
chronous primary cancers (cancers diagnosed within 6
months after first diagnosis) and patients with less than
6 months of follow-up were excluded from the main
analyses.
We calculated standardized incidence ratios (SIR) (in-
direct standardization) to estimate relative risks (RR) of
metachronous SPC in cancer survivors compared with
the cancer risk of the general population [13, 31]. SIR
were calculated for all cancers combined (ICD-10 C00-
C97 excl. C44) and for 23 common cancer types (19 for
males and 21 for females). In addition, the we stratified
risk calculations by age at first diagnosis (0–49 years,
50–64 years, 65 years and over), time of first diagnosis
(1981–1989, 1990–1999, 2000–2009), and follow-up
interval (6 months to less than 1 year, 1 year to less than
5 years, 5 years to less than 10 years, 10 years or longer).
Analyses by period of first diagnosis were restricted to
10 years of follow-up to enhance comparability across
time. For the five initial cancer types showing the high-
est risks of developing a SPC and for all first cancer
types combined, the RR of SPC were analysed stratified
by type of SPC. Person-years at risk were calculated
from the 6th month after diagnosis. The comparison
cohort (general population) consisted of all permanent
residents living between 1981 and 2014 in the catchment
area of the included cantonal cancer registries. To calcu-
late the expected number of SPC in the cohort of cancer
survivors, we used sex, age- and calendar year-specific
incidence rates (5-year age categories) of the general
population [17]. Confidence intervals at the 95% level
(95%CI) for the SIR were produced assuming a Poisson
distribution [32]. 95%CI not including 1 were catego-
rized as significant at p-level < 0.05 [33]. We did not
account for multiple comparisons. Significant results
have to be interpreted exploratorily.
To investigate the potential effect of detection bias, we
additionally calculated the RR of SPC for the time period
0-6th month (synchronous tumours) and for total risks
including the first 6 months after initial diagnosis for
risk calculations (sensitivity analyses).
In our analyses, we adjusted for age and calendar
period, therefore improved survival/aging itself does not
increase risk estimates. However, as long-term survivors
might be affected by additional risk factors (e.g. long-
term and late effects of treatment), we additionally esti-
mated 5-year survival proportions by sex and cancer site
using the Kaplan-Meier method.
The multiple imputation of, as well as the calculations
of, background risks were carried out using Stata/MP
version 15.0 (STAT Corp., TX USA). All further analyses
were performed in R (Version 3.4.3).
Results
The characteristics of the study cohort are presented in
Table 1. A total of 33,793 SPC occurred in 310,113 can-
cer patients over 2,390,410 person-years at risk (median
follow-up 6.0 years, interquartile range 2.1 to 10.9 years
per person). Almost 40% of SPC were diagnosed be-
tween 1 and 5 years after first diagnosis, and nearly one
third each were diagnosed 5 to 10 years after first diag-
nosis or afterwards. The five most common SPC were
prostate cancer (28.5%), colorectal cancer (14.2%), can-
cer of the oral cavity and pharynx (8.5%), bladder cancer
(7.3%) and melanoma (6.4%) in males, and breast cancer
(36.8%), colorectal cancer (11.7%), cancer of the corpus
uteri (9.4%), melanoma (7.2%) and non-Hodgkin lymph-
oma (3.6%) in females.
Relative risk of second primary cancers by type of first
primary cancer and sex
Overall, both male (SIR 1.18, 95%CI 1.16–1.19) and fe-
male (SIR 1.20, 95%CI 1.18–1.22) cancer survivors had
an elevated risk of developing a SPC compared with the
general population (Fig. 1). In males, 18 out of 19 first
primary cancer types investigated were associated with
an increased risk for SPC. The RR was statistically sig-
nificant for all cancer types with the notable exception
of pancreatic cancer (SIR 1.34, 95%CI 0.96–1.73) and
multiple myeloma (SIR 1.13, 95%CI 0.95–1.31). A sig-
nificantly reduced risk was observed for prostate cancer
(SIR 0.75, 95%CI 0.73–0.77) (Fig. 1), which remained
after including tumours diagnosed within the first 6
months after initial diagnosis (SIR 0.80, 95%CI 0.78–
0.82) (Additional file 1: Figure S1). In females, the risk of
SPC was increased in 19 out of 21 cancer sites, though
not reaching statistical significance for multiple myeloma
(SIR 1.16, 95%CI 0.92–1.39). The highest SIR were ob-
served for cancers of the oral cavity and pharynx, Hodg-
kin lymphoma, laryngeal cancer, oesophageal cancer,
and lung cancer. For female breast cancer, the observed
risk of SPC was similar to the general population (SIR
0.98, 95%CI 0.95–1.01).
Including synchronous tumours (Additional file 1: Table
S1 and Figure S1) resulted in higher risk estimates in both
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Table 1 Characteristics of the study cohort
First Primary Cancers Second Primary Cancers
N % N %
Sex
Males 155,214 50.1 19,811 58.6
Females 154,899 49.9 13,982 41.4
Age at diagnosis
15–49 years 54,930 17.7 1250 3.7
50–64 years 93,939 30.3 6708 19.9
65 years and over 161,244 52.0 25,835 76.5
Period of diagnosis
1981–1984 27,063 8.7 411 1.2
1985–1989 39,184 12.6 1971 5.8
1990–1994 47,624 15.4 3364 10.0
1995–1999 57,764 18.6 4724 14.0
2000–2004 67,145 21.7 6566 19.4
2005–2009 71,333 23.0 8635 25.6
2010–2014 n.a* 8122 24.0
Follow-up interval
6 month to less than 1 year n.a.** 2098 6.2
1 years to less than 5 years n.a.** 12,532 37.1
5 years to less than 10 years n.a.** 10,011 29.6
10 years and longer n.a.** 9152 27.1
Type of primary cancer
Cavity & Pharynx (C00-C14) 8465 2.7 1565 4.6
Oesophagus (C15) 3055 1.0 785 2.3
Stomach (C16) 7663 2.5 1056 3.1
Colorectal (C18-C20) 35,949 11.6 4353 12.9
Extrahepatic Bile Ducts (C22) 2780 0.9 768 2.3
Pancreas (C25) 4534 1.5 1267 3.7
Larynx (C32) 2575 0.8 367 1.1
Lung (C33-C34) 24,539 7.9 5152 15.2
Melanoma (C43) 17,794 5.7 1662 4.9
Breast female (C50) 59,453 19.2 2597 7.7
Cervix uteri (C53) 4080 1.3 125 0.4
Corpus uteri & NOS (C54-C55) 9710 3.1 876 2.6
Ovary (C56) 6067 2.0 530 1.6
Prostate (C61) 48,311 15.6 3694 10.9
Testis (C62) 4912 1.6 36 0.1
Kidney (C64) 6210 2.0 812 2.4
Bladder (C67) 9801 3.2 1387 4.1
Brain & Central Nerves (C70-C72) 4072 1.3 403 1.2
Thyroid (C73) 4360 1.4 414 1.2
Hodgkin Lymphoma (C81) 2481 0.8 123 0.4
non-Hodgkin Lymphoma (C82-C86, C96) 11,340 3.7 1301 3.8
Multiple Myeloma (C90) 4298 1.4 487 1.4
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sexes (males: SIR 1.32, 95%CI 1.31–1.34; females: SIR 1.29,
95%CI 1.27–1.31) and for all cancer types investigated. A
major shift from reduced (main analyses, Fig. 1) to in-
creased risk (sensitivity analyses, Additional file 1: Figure
S1) was only observed for female pancreatic cancer. For all
other initial cancer types, we observed low to moderate
increases, but consistent directions in risk estimates.
The lowest 5-year survival in both sexes were observed
for pancreatic (< 5%) and liver cancer (< 10%) (Add-
itional file 1: Table S2). For most initial cancers, women
had improved survival compared to men resulting in an
overall 5-year survival of 42.2 and 53.0% in males and
females, respectively.
Relative risk of second primary cancer by type of first
primary cancer and age at diagnosis
Overall, the risk of SPC compared with the general popula-
tion was elevated for each of the three age-groups, and
tended to decrease with increasing age at first diagnosis
(Table 2).
Significantly elevated risks across all age-groups were
observed following cancer of the oral cavity and pharynx,
oesophageal cancer, colorectal cancer, laryngeal cancer,
lung cancer, melanoma, cervical cancer, cancer of the cor-
pus uteri, kidney cancer, bladder cancer, thyroid cancer,
Hodgkin lymphoma and leukaemia. Risk were greater
among patient who had primary cancer at youngest age
for oral cavity, esophagus, colorectal, liver, lung cancers
and Hodgkin and non-Hodgkin lymphoma.
For female breast cancer, risk estimates of SPC across
all age-groups were comparable to those of the general
population (Table 2). Multiple myeloma patients had in-
creased risks across age-groups, albeit not reaching stat-
istical significance. For prostate cancer patients, a
reduced risk of SPC was observed for men aged 50 years
and above, but not for men diagnosed before the age of
50 years. For the remaining cancer types (stomach, liver,
pancreas, ovary, testicles) risks were significantly in-
creased for at least one age-group (< 50 years and/or 50–
64 years at initial diagnosis).
Relative risk of second primary cancers by type of first
primary cancer and survival period
The risk of SPC for all initial cancers combined was sig-
nificantly increased during each survival period showing
a rising trend with increasing time since initial diagnosis
(Table 3). In addition, significantly elevated risks across
all survival periods were observed following cancers of
the oral cavity and pharynx, oesopaghus,larynx, lung,
kidney and bladder. From 10 years on after initial diag-
nosis, all cancer sites exhibited significantly elevated RR
except pancreatic cancer, multiple myeloma and prostate
cancer. Of note, prostate cancer survivors had signifi-
cantly lower risk of subsequent cancer than the general
population. For breast cancer survivors, the risk of devel-
oping a SPC was comparable to that of the general
population up to 10 years after diagnosis, but increased
thereafter.
Relative risk of second primary cancer by type of first
primary cancer and time period of first diagnosis
For all initial cancers combined andmost cancer sites, no
clear trends in risk estimates were observed by time period
of first diagnosis (Table 4). However, among patients ini-
tially diagnosed with a cancer of the larynx, corpus uteri,
bladder or thyroid those diagnosed more recently tended
to have a higher risk than those diagnosed earlier. For all
initial cancers combined, significantly increased risks were
observed for the first (1981–1989: SIR 1.21, 95%CI 1.07–
1.36) and last period (2000–2009: SIR 1.17, 95% CI 1.05–
1.28), but not for the intermediate period (1990–1999: SIR
1.14, 95%CI 1.00–1.28). However, to allow comparisons
that are more consistent across time, these analyses were
restricted to 10 years of follow-up, excluding 9152 SPCs
and 565,995 person-years from calculation.
Relative risk of second primary cancers by type of first
and second primary cancer and sex
Figure 2 presents the RR estimates (limited to statisti-
cally significant results) by type of SPC for the five first
primary cancers with the highest RR of SPC. Complete
lists of calculated risk estimates are supplied in
Additional file 1: Table S3, S4, S5, S6 and S7.
The strongest combinations of initial cancer and SPC
(SIR > = 20) were observed for:
 cancer of the oral cavity and pharynx – oral cavity
and pharynx (both sexes)
 cancer of the oral cavity and pharynx – laryngeal
cancer (females)
Table 1 Characteristics of the study cohort (Continued)
First Primary Cancers Second Primary Cancers
N % N %
Leukemia (C91-C95) 7933 2.6 1062 3.1
Others 19,731 6.4 2971 8.8
All cancers 310,113 100.0 33,793 100.0
* n.a.: not applicable; the study cohort includes first primary cancers of the period 1981–2009
**n.a.: not applicable; follow-up interval refers to the interval between first and second primary cancer
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Fig. 1 Relative risk of second primary cancers by type of first primary cancer and sex. a Males, b Females. 95%CI: 95%-confidence interval. Relative
risks were estimated by standardized incidence ratios
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 cancer of the oral cavity and pharynx – oesophageal
cancer (females)
 laryngeal cancer – oral cavity and pharynx (females).
Overall, an initial diagnosis with cancer of the oral cavity
and pharynx was associated with significantly increased
risks for 10 (out of 19) and 7 (out of 21) types of SPC in
males and females, respectively. Similarly, lung cancer
showed elevated risks for 9 specific SPC in males and 5 in
females. Corresponding figures for initial laryngeal cancer
and oesophageal cancer were 6 and 2, and 2 and 1 specific
SPC types in males and females, respectively.
In patients initially diagnosed with Hodgkin lymphoma
significantly elevated risks estimates were observed for
second non-Hodgkin lymphoma and lung cancer in
males, and second leukemia, cancer of the oral cavity
and pharynx, bladder and breast in females.
For all initial cancers combined, we observed signifi-
cantly increased risks for 17 out of 19 specific SPC types
in males and 17 out of 21 specific SPC types in females,
ranging overall from SIR 1.18 (95%CI 1.13–1.22, colorectal
cancer in males) to SIR 2.53 (95%CI 2.38–2.68, cancer of
the oral cavity and pharynx in males) (Table 5). In con-
trast, male cancer survivors had a significantly reduced
risk of developing second prostate cancer (SIR 0.67,
95%CI 0.65–0.70) and female cancer survivors a reduced
risk of developing second breast (SIR 0.74, 95%CI 0.71–
0.77) and cervical cancers (SIR 0.82, 95%CI 0.66–0.98).
Discussion
Summary of main findings
Overall, Swiss cancer survivors had a moderate excess risk
of SPC (about 20% in both sexes) compared to the general
population. SPC risks varied substantially according to site
of first primary cancer and were highest among patients
initially diagnosed with cancer of the oral cavity and phar-
ynx, larynx, oesophagus, lung and Hodgkin lymphoma.
Prostate cancer survivors had a significantly reduced risk
Table 2 Relative risk of second primary cancer by site of first primary cancer and age at first diagnosis
0–49 years 50–64 years 65+ years
First primary cancer O E SIR 95%CI O E SIR 95%CI O E SIR 95%CI
Oral Cavity & Pharynx 403 61 6.61 (5.94–7.28) 1103 293 3.76 (3.54–3.99) 665 324 2.05 (1.89–2.21)
Oesophagus 30 4 8.03 (4.80–11.25) 118 41 2.89 (2.33–3.44) 96 61 1.57 (1.24–1.91)
Stomach 49 27 1.79 (1.24–2.34) 205 144 1.43 (1.22–1.63) 317 292 1.09 (0.96–1.21)
Colorectal 251 139 1.81 (1.58–2.04) 1376 1086 1.27 (1.20–1.34) 2814 2576 1.09 (1.05–1.13)
Liver & Intrahepatic Bile Ducts 17 3 5.39 (2.40–8.37) 44 29 1.50 (1.01–1.99) 62 54 1.16 (0.85–1.47)
Pancreas 4 3 1.14 (0.00–2.65) 37 23 1.61 (1.03–2.18) 51 53 0.97 (0.68–1.26)
Larynx 91 26 3.56 (2.78–4.35) 470 160 2.94 (2.66–3.21) 332 176 1.88 (1.67–2.09)
Lung 120 40 3.00 (2.43–3.57) 671 339 1.98 (1.82–2.13) 769 533 1.44 (1.34–1.55)
Skin Melanoma 386 291 1.33 (1.19–1.46) 807 668 1.21 (1.12–1.29) 1083 904 1.20 (1.12–1.27)
Breast female 748 766 0.98 (0.90–1.05) 2041 2023 1.01 (0.96–1.05) 2356 2456 0.96 (0.92–1.00)
Cervix Uteri 169 104 1.63 (1.37–1.88) 163 93 1.75 (1.47–2.04) 126 88 1.43 (1.17–1.70)
Corpus Uteri & NOS 90 54 1.66 (1.29–2.03) 581 460 1.26 (1.16–1.37) 650 576 1.13 (1.04–1.22)
Ovary 74 48 1.56 (1.17–1.94) 155 119 1.30 (1.08–1.51) 138 124 1.11 (0.92–1.31)
Prostate 17 15 1.15 (0.51–1.79) 1269 1656 0.77 (0.72–0.81) 4352 5806 0.75 (0.73–0.77)
Testis 239 172 1.39 (1.21–1.58) 86 64 1.34 (1.03–1.64) 22 13 1.75 (0.91–2.59)
Kidney 71 42 1.69 (1.27–2.12) 331 240 1.38 (1.23–1.54) 464 370 1.25 (1.14–1.37)
Bladder 68 32 2.10 (1.56–2.64) 588 352 1.67 (1.53–1.81) 1087 781 1.39 (1.31–1.48)
Brain & Central Nerves 51 25 2.05 (1.43–2.66) 43 35 1.24 (0.83–1.65) 19 19 0.99 (0.48–1.50)
Thyroid 152 102 1.49 (1.24–1.74) 191 129 1.48 (1.26–1.70) 158 121 1.31 (1.09–1.53)
Hodgkin Lymphoma 174 53 3.31 (2.79–3.83) 91 40 2.27 (1.77–2.77) 58 33 1.77 (1.27–2.26)
Non Hodgkin Lymphoma 162 84 1.92 (1.61–2.23) 472 337 1.40 (1.27–1.53) 689 532 1.30 (1.20–1.40)
Multiple Myeloma 14 11 1.30 (0.50–2.11) 85 75 1.14 (0.88–1.40) 194 171 1.13 (0.96–1.30)
Leukaemia 96 40 2.43 (1.91–2.95) 334 196 1.70 (1.51–1.89) 528 377 1.40 (1.28–1.52)
All Cancers 3783 2256 1.68 (1.62–1.73) 11,920 9014 1.32 (1.30–1.35) 18,090 17,190 1.05 (1.04–1.07)
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals
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Table 3 Relative risk of second primary cancer by type of first primary cancer and follow-up period
6 months to 1 year 1 year to 5 years 5 years to 10 years Over 10 years
First primary cancer O E SIR 95%CI O E SIR 95%CI O E SIR 95%CI O E SIR 95%CI
Oral Cavity &
Pharynx
166 51 3.28 (2.75–
3.80)
971 274 3.54 (3.31–
3.77)
636 200 3.18 (2.93–
3.44)
398 154 2.59 (2.33–
2.86)
Oesophagus 30 17 1.78 (1.06–
2.49)
131 52 2.51 (2.06–
2.97)
47 24 1.97 (1.35–
2.59)
36 13 2.82 (1.79–
3.84)
Stomach 46 47 0.98 (0.67–
1.30)
205 188 1.09 (0.93–
1.25)
163 122 1.34 (1.12–
1.55)
157 106 1.48 (1.24–
1.73)
Colorectal 280 260 1.08 (0.95–
1.21)
1671 1523 1.10 (1.04–
1.15)
1332 1118 1.19 (1.13–
1.26)




20 16 1.26 (0.62–
1.89)
58 49 1.19 (0.85–
1.52)
28 16 1.77 (1.03–
2.52)
17 5 3.13 (1.40–
4.87)
Pancreas 18 21 0.87 (0.40–
1.33)
45 39 1.15 (0.78–
1.52)
16 12 1.30 (0.56–
2.05)
13 7 1.86 (0.66–
3.06)
Larynx 53 20 2.61 (1.84–
3.37)
361 130 2.77 (2.47–
3.06)
256 110 2.34 (2.04–
2.63)
223 102 2.19 (1.89–
2.50)
Lung 201 136 1.47 (1.26–
1.69)
642 420 1.53 (1.41–
1.65)
411 214 1.92 (1.73–
2.11)
306 143 2.15 (1.90–
2.40)
Skin Melanoma 113 89 1.28 (1.03–
1.52)
709 631 1.12 (1.04–
1.21)
687 561 1.22 (1.13–
1.32)
767 583 1.32 (1.22–
1.41)
Breast female 197 252 0.78 (0.67–
0.90)
1532 1807 0.85 (0.80–
0.89)
1632 1617 1.01 (0.96–
1.06)
1784 1570 1.14 (1.08–
1.19)
Cervix Uteri 16 12 1.31 (0.56–
2.06)
108 75 1.45 (1.16–
1.74)
124 73 1.69 (1.38–
2.01)
210 125 1.68 (1.44–
1.92)
Corpus Uteri & NOS 46 49 0.95 (0.65–
1.25)
386 335 1.15 (1.03–
1.27)
359 320 1.12 (1.00–
1.24)
530 386 1.37 (1.25–
1.49)
Ovary 20 23 0.86 (0.43–
1.30)
105 113 0.93 (0.74–
1.12)
102 75 1.36 (1.08–
1.65)
140 80 1.75 (1.44–
2.05)
Prostate 348 509 0.68 (0.61–
0.76)
2423 3409 0.71 (0.68–
0.74)
1868 2461 0.76 (0.72–
0.79)
999 1098 0.91 (0.85–
0.97)
Testis 7 5 1.55 (0.10–
3.00)
63 39 1.60 (1.17–
2.03)
70 53 1.33 (0.99–
1.67)
207 152 1.36 (1.17–
1.56)
Kidney 65 40 1.64 (1.21–
2.07)
318 251 1.27 (1.12–
1.41)
243 198 1.23 (1.07–
1.39)
240 164 1.47 (1.27–
1.66)
Bladder 150 85 1.77 (1.47–
2.06)
679 476 1.43 (1.32–
1.54)
483 338 1.43 (1.30–
1.56)




15 10 1.52 (0.62–
2.43)
38 30 1.27 (0.82–
1.72)
25 20 1.26 (0.70–
1.82)
35 19 1.83 (1.15–
2.50)
Thyroid 20 14 1.46 (0.73–
2.20)
151 103 1.46 (1.22–
1.71)
125 104 1.20 (0.98–
1.42)
205 131 1.57 (1.34–
1.80)
Hodgkin Lymphoma 8 5 1.53 (0.21–
2.85)
99 34 2.89 (2.28–
3.49)
70 33 2.09 (1.56–
2.62)




81 64 1.26 (0.97–
1.56)
494 388 1.27 (1.16–
1.39)
401 286 1.40 (1.26–
1.54)
347 215 1.62 (1.44–
1.79)
Multiple Myeloma 21 28 0.75 (0.38–
1.12)
145 140 1.04 (0.86–
1.21)
91 63 1.44 (1.13–
1.76)
36 26 1.38 (0.88–
1.88)
Leukaemia 51 45 1.14 (0.80–
1.48)
971 266 1.43 (1.29–
1.58)
308 183 1.68 (1.49–
1.88)
218 119 1.83 (1.57–
2.08)












9152 6706 1.36 (1.34–
1.39)
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals
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of developing a SPC and no excess risk of SPC was found
in female breast cancer patients, apart beyond 10 years
after first diagnosis. Overall and for most initial cancers, a
tendency towards higher RR was observed in patients first
diagnosed at younger ages. Stratified by survival period,
risk estimates increased with time since first diagnosis.
Our data also further confirmed strong associations be-
tween particular types of first and SPC, mainly for cancers
caused by smoking. For example, Swiss males and females
initially diagnosed with cancer of the oral cavity and phar-
ynx had a 20-fold and almost 40-fold increased risk of be-
ing diagnosed with a second cancer of the oral cavity and
pharynx, and a 16-fold and almost 30-fold increased risk
of being confronted with a second oesophageal cancer,
respectively.
Discussion in the context of the literature
In line with our Swiss results, studies conducted in other
high-income countries reported an increased risk for
cancer survivors of being diagnosed with SPC compared
to the cancer risk within the general population [12–17,
34]. However, overall increased risks of subsequent
cancers were not systematically observed for all regions
or countries and time periods investigated. A recent can-
cer registry study from Austria, for example, observed
increased risks for single cancer sites, but no overall
increased risk [35]. An Italian population-based study
reported an overall significantly reduced risk (SIR 0.87)
although the population size covered (< 2.5 million in-
habitants in total) and the length of follow-up (mean:
2.5 years, < 50,000 person-years of follow-up) were rela-
tively limited [36].
Excess risk of SPC is usually explained by common
aetiologic risk factors (i.e. lifestyle, environmental expo-
sures and genetics) and/or late effects of cancer treatment
(i.e. radiotherapy and chemotherapy). Smoking and alco-
hol consumption are clearly associated with an elevated
risk of various cancers [37], and the multiplicative effect of
Table 4 Relative risk of second primary cancer by type of first primary cancer and time period
1981–1989 1990–1999 2000–2009
First primary cancer O E SIR 95%CI O E SIR 95%CI O E SIR 95%CI
Oral Cavity & Pharynx 385 115 3.36 (2.89–3.82) 681 190 3.58 (3.21–3.95) 707 210 3.37 (3.05–3.70)
Oesophagus 32 11 2.93 (1.79–4.08) 79 31 2.54 (1.93–3.15) 97 50 1.95 (1.52–2.38)
Stomach 117 100 1.18 (0.90–1.45) 165 134 1.24 (0.98–1.49) 132 112 1.18 (0.92–1.44)
Colorectal 761 628 1.22 (1.01–1.43) 1183 1028 1.16 (0.96–1.36) 1339 1137 1.18 (1.00–1.37)
Liver & Intrahepatic Bile Ducts 9 5 1.79 (0.35–3.23) 25 22 1.12 (0.62–1.63) 72 52 1.37 (1.03–1.72)
Pancreas 15 11 1.34 (0.53–2.15) 22 23 0.98 (0.50–1.45) 42 37 1.14 (0.75–1.53)
Larynx 170 73 2.32 (1.92–2.71) 247 94 2.63 (2.27–3.00) 253 89 2.83 (2.44–3.23)
Lung 291 171 1.70 (1.49–1.91) 433 266 1.63 (1.46–1.80) 530 325 1.63 (1.47–1.79)
Skin Melanoma 264 212 1.25 (1.05–1.44) 536 441 1.22 (1.05–1.39) 709 593 1.20 (1.04–1.36)
Breast female 721 756 0.96 (0.81–1.10) 1205 1301 0.93 (0.81–1.05) 1435 1516 0.95 (0.85–1.05)
Cervix Uteri 97 57 1.71 (1.34–2.08) 86 61 1.42 (1.08–1.75) 65 40 1.63 (1.18–2.07)
Corpus Uteri & NOS 197 193 1.02 (0.86–1.19) 285 251 1.14 (0.96–1.31) 309 243 1.27 (1.08–1.47)
Ovary 57 48 1.18 (0.84–1.52) 100 78 1.28 (1.00–1.56) 70 81 0.86 (0.64–1.09)
Prostate 608 858 0.71 (0.59–0.84) 1544 2203 0.70 (0.60–0.81) 2487 3137 0.79 (0.72–0.87)
Testis 31 22 1.43 (0.86–1.99) 54 38 1.43 (1.01–1.85) 55 37 1.49 (1.06–1.92)
Kidney 123 95 1.29 (1.03–1.55) 207 186 1.11 (0.94–1.29) 296 197 1.50 (1.28–1.72)
Bladder 328 242 1.36 (1.14–1.58) 514 352 1.47 (1.22–1.71) 470 277 1.70 (1.43–1.98)
Brain & Central Nerves 15 10 1.43 (0.58–2.28) 24 22 1.11 (0.60–1.62) 39 27 1.43 (0.93–1.93)
Thyroid 58 48 1.22 (0.87–1.57) 102 76 1.35 (1.06–1.64) 136 95 1.44 (1.18–1.70)
Hodgkin Lymphoma 41 17 2.40 (1.58–3.21) 59 26 2.27 (1.63–2.90) 77 29 2.63 (1.99–3.27)
Non Hodgkin Lymphoma 185 138 1.34 (1.10–1.59) 347 265 1.31 (1.13–1.50) 444 318 1.40 (1.21–1.59)
Multiple Myeloma 58 45 1.28 (0.91–1.66) 83 77 1.08 (0.81–1.35) 116 103 1.12 (0.89–1.36)
Leukaemia 167 106 1.58 (1.27–1.89) 246 168 1.47 (1.21–1.73) 327 206 1.59 (1.35–1.84)
All Cancers 5052 4172 1.21 (1.07–1.36) 8752 7679 1.14 (1.00–1.28) 10,837 9308 1.17 (1.05–1.28)
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals
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Fig. 2 Relative risk of second primary cancer for selected first primary cancer sites by type of second primary cancer and sex. a Males, b Females.
Relative risks were estimated by standardized incidence ratios
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both factors can substantially exceed the risk from either
factor alone for some cancer sites [37]. Consequently,
smokers/regular drinkers diagnosed with a smoking/al-
cohol-associated cancer have an elevated risk of devel-
oping a second smoking/alcohol associated cancer [11,
38]. Overall, smoking and alcohol-associated cancers
accounted for a substantial proportion of first and sec-
ond primary cancers in our study population. Many
cancers are known to have a multifactorial etiology and
some cancer treatments are known to be carcinogenic.
For example, known risk factors for breast cancer in-
clude age, genetics, being overweight, exposure to es-
trogen, alcohol consumption and others. For other
cancers, such as Hodgkin lymphoma, the aetiology of
disease remains largely unknown [39]. Due to the lack
of data on risk factors and treatment in our study,
underlying mechanisms could not be investigated and
are therefore speculative.
In line with other studies outside of Switzerland [35,
40], we observed a significantly reduced risk of SPC for
prostate cancer survivors. Prostate cancer is the most
common cancer in males, leading to high numbers of
expected cases. However, our risk of subsequent prostate
cancer might be overestimated. Overall, more than 50%
of patients with first prostate cancer are treated with
surgery including radical prostatectomy [41]. In
Switzerland, prostate cancer incidence rates have re-
cently decreased after a sustained increase up to 2002,
most likely due to changes in screening and work-up
practices [42]. Higher socioeconomic position (SEP) has
been shown to be associated with more frequent
prostate-specific antigen (PSA) screening, earlier diagno-
sis [28, 43] and higher prostate cancer incidence com-
pared to men with lower SEP. [44, 45] In addition, men
of higher SEP are generally more health conscious than
the general male population [46] and thus less likely to
Table 5 Relative risk of second primary cancer for any first primary cancer by type of second primary cancer and sex
Males Females
Second primary cancer O E SIR 95%CI O E SIR 95%CI
Oral Cavity & Pharynx 1136 449.60 2.53 (2.38–2.68) 429 189.05 2.27 (2.05–2.49)
Oesophagus 566 293.21 1.93 (1.76–2.10) 219 96.60 2.27 (1.95–2.59)
Stomach 670 528.41 1.27 (1.17–1.37) 386 299.80 1.29 (1.15–1.42)
Colorectal 2430 2066.81 1.18 (1.13–1.22) 1923 1470.15 1.31 (1.25–1.37)
Liver & Intrahepatic Bile Ducts 576 453.56 1.27 (1.16–1.38) 192 137.66 1.39 (1.19–1.60)
Pancreas 669 490.60 1.36 (1.26–1.47) 598 469.70 1.27 (1.17–1.38)
Larynx 317 179.31 1.77 (1.56–1.97) 50 26.04 1.92 (1.31–5.53)
Lung 3551 2262.39 1.57 (1.52–1.62) 1601 891.66 1.80 (1.71–1.88)
Skin Melanoma 926 670.74 1.38 (1.29–1.47) 736 513.03 1.43 (1.33–1.54)
Breast female – – – – 2597 3515.70 0.74 (0.71–0.77)
Cervix Uteri – – – – 125 152.49 0.82 (0.66–0.98)
Corpus Uteri & NOS – – – – 876 674.95 1.30 (1.21–1.39)
Ovary – – – – 530 437.46 1.21 (1.10–1.32)
Prostate 3694 5486.76 0.67 (0.65–0.70) – – – –
Testis 36 49.08 0.73 (0.45–1.02) – – – –
Kidney 537 396.46 1.35 (1.23–1.47) 275 196.64 1.40 (1.22–1.57)
Bladder 1053 855.25 1.23 (1.16–1.31) 334 238.59 1.40 (1.24–1.56)
Brain & Central Nerves 242 184.26 1.31 (1.14–1.49) 161 139.94 1.15 (0.96–1.34)
Thyroid 143 60.76 2.35 (1.93–2.77) 271 156.18 1.74 (1.52–1.95)
Hodgkin Lymphoma 67 39.21 1.71 (1.25–2.17) 56 28.16 1.99 (1.39–2.58)
Non Hodgkin Lymphoma 733 539.77 1.36 (1.26–1.46) 568 440.42 1.29 (1.18–1.40)
Multiple Myeloma 291 231.10 1.26 (1.11–1.41) 196 188.29 1.04 (0.88–1.20)
Leukaemia 590 428.02 1.38 (1.26–1.49) 472 283.12 1.67 (1.51–1.82)
All Cancers 18,811 16,827.19 1.18 (1.16–1.19) 13,982 11,631.97 1.20 (1.18–1.22)
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals
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be exposed to cancer risk such as cigarette smoking and
alcohol consumption.
Similarly, breast cancer is the most common cancer in
females leading to high number of expected second
breast cancers. However, women treated with mastec-
tomy are not at risk for ipsilateral breast cancer [47].
Concerning SEP and mammography use, the Swiss find-
ings are mixed [48, 49], but we recently reported that
women of higher SEP compared to women of lower SEP
are more likely to be diagnosed at an early stage [50]. In
our present study, breast cancer survivors in general had
a similar risk of SPC than the general female population,
although an increased risk of SPC was observed in the
youngest age-group (< 50 years at time of diagnosis). The
latter finding might be related to factors such as cancer-
predisposition genes [51] or more aggressive treatment
schemes [52].
In line with other studies [11, 13, 17, 35], we found a
consistent pattern of higher risks of SPC for young-
onset patients. Notably, longer residual life expectancy
itself is insufficient to explain our results as we calcu-
lated age-adjusted risks. However, improved survival in
younger patients may increase the likelihood of experi-
encing adverse long-term treatment effects. Further,
younger patients may receive more aggressive treatment
[53, 54] and might differ from older patients in various
respects such as genetic predisposition, risk factor pat-
terns, etc.
SPC may occur months or years after the first cancer
was diagnosed. However, SPC caused by first cancer
treatment are expected to occur many years after the
first diagnosis [55]. For therapy-associated solid tu-
mours, the latency period is typically 10 years or more.
Treatment-related leukemia occurs with a shorter la-
tency, peaking between 5 to 10 years after diagnosis [55].
In our study, the risk of SPC was significantly increased
during each follow-up period with a substantial increase
at 5 to 10 years and over 10 years post-diagnosis. This is
in contrast to studies from Australia and the US, which
reported increased risks of SPC but no relevant changes
by follow-up period.
In the US and Australia, the risk of SPC appears to
have increased since the 1980s [56]. However, whether
increased radiation exposure and/or changed treatment
modalities contributed to this finding is not determined
[56]. Interestingly, the rise over time in SPC found for
thyroid cancer in the present study largely concur with
the advent of growing thyroid cancer incidence most
likely related to screening and increased overdiagnosis
[57]. Overall, we observed no clear temporal trends after
stratification by time period. For all cancer sites com-
bined, we found a significantly increased risk of SPC for
the first and last time period, but not for the intermedi-
ate one. However, these analyses were restricted to 10
years of follow-up, excluding a substantial number of
SPCs and person-years from calculation.
Patterns of first and second primary cancers were fur-
ther analysed for the five cancers with the highest RR
of SPC, out of which four are highly related to smoking
(Fig. 2). Our results confirmed mutual increased risks
between tobacco-related cancer types [13, 17]. For pa-
tients with Hodgkin lymphoma, a cancer of largely un-
known aetiology [39], the RR of SPC ranked second in
males and third in females. Previous studies have
shown that Hodgkin lymphoma is associated with in-
creased risks for both second solid tumours and
hematologic malignancies which persist for many de-
cades after treatment [58, 59]. The risk of SPC follow-
ing Hodgkin lymphoma seems to be influenced by
various factors including age at treatment [58, 59],
treatment type [58], smoking [60] and family history of
cancer [59]. We confirmed an increased risk of second
non-Hodgkin lymphoma and leukaemia among Hodg-
kin lymphoma patients, as well as increased risks for
second breast cancer and lung cancer but not for other
second malignancies as reported previously [58, 59].
Strengths and limitations
This is the largest population-based investigation of SPC
among cancer survivors in Switzerland, providing the
most representative nationwide findings to date. This
study was based on data from population-based regis-
tries of high quality and high completeness of case ascer-
tainment [20].
However, there are several methodological aspects to
point out. First, there are no universally agreed criteria
to identify multiple primary cancers. Currently, mainly
two definitions of multiple primaries are used, one from
the Surveillance Epidemiology and End Results (SEER)
Program [61], the other from the IACR and the IARC
[62]. Although both definitions take site and histology
into account, the definition of the SEER Program are
more complex and classify more cases as multiple pri-
mary cancers (i.e. cancers diagnosed at the same site, in
paired organs and/or with similar histology) than the
IACR/IARC definition [63]. A detailed description and
comparison of both definitions and rules can be found
elsewhere [63]. For this study, we applied the IACR/
IARC rules, resulting in more conservative risk estimates
than those based on the SEER definition [40]. The im-
pact of these different definitions has been assessed in
Scotland, based on data of 10 pooled cancer sites with 5-
year follow-up, resulting in a SIR of 0.86 and a SIR of
1.0 when applying the IACR/IARC and SEER rules, re-
spectively. A large difference was reported however for
repeated breast cancer in women, of which 79 of 98 sub-
sequent breast cancers were classified as SPC by SEER,
but only 1 by IACR/IARC [40]. In addition, there is no
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common definition of second or metachronous tumours.
We used a 6-month delay as cut-off between synchron-
ous and metachronous tumours [22]. However, shorter
limits have also been used [13, 16, 17]. Finally, a few
authors classified all subsequent tumours as metachro-
nous, irrespective of time lag between first and second
cancer diagnosis [64, 65]. Our sensitivity analysis, includ-
ing primary cancers occurring within 6 months after ini-
tial diagnosis, revealed higher risk estimates than our
main analyses. Consequently, our estimates are likely to
be conservative.
The gradual implementation of regional cancer regis-
tration in Switzerland means that some SPC may have
been wrongly classified as first cancers if the true first
cancer was diagnosed prior to the implementation of
cancer registration in that region. However, the magni-
tude of this bias is likely to be small. In France, based on
data of a single cancer registry collecting data since
1958, a comparison of RR estimates of SPC obtained
over fictional registration periods beginning 10 years, 5
years and 0 years before the study period reported small
overestimations of RR of 0.1, 0.6, and 0.6%, respectively.
Although overall completeness of case ascertainment in
Switzerland is high, potential underregistration of lymph-
oid leukemia was consistently observed across cancer
registries [20]. For the cancer registry of Basel, potential
underregistration was also reported for liver, pancreatic
and ovarial cancer; for the cancer registry of Zurich also
for non-Hodgkin lymphoma and ovarial, prostate and kid-
ney cancer. At the national level (all registries combined),
ovarial cancer, prostate cancer and lymphoid leukemia
showed suspicious results regarding completeness. Conse-
quently, it cannot be ruled out that some of the presented
estimates are affected by underregistration. However, our
results correspond very well to the results published from
countries with high completeness of cancer registration,
such as Denmark, Finland and Norway [12, 15, 18].
Finally, we cannot exclude chance findings resulting
from multiple comparisons, or the possibility that genu-
ine effects have been missed due to low statistical power
for some comparisons.
Conclusions
Swiss cancer survivors have an increased risk of develop-
ing a SPC compared to the general population. This risk
is especially high among patients first diagnosed before
age 50 years and those surviving at least 10 years. Cancer
patients should remain under continued surveillance not
only for recurrent cancers but also for new primary can-
cers. First and second cancers that share common life-
style associated risk factors are rather common and
underlines the importance to promote healthier lifestyles
in both the general population and cancer survivors.
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